Application of machine learning methods to pathogen safety evaluation in biological manufacturing processes

Abstract

The production of recombinant therapeutic proteins from animal or human cell lines entails the risk of endogenous viral contamination from cell substrates and adventitious agents from raw materials and environment. One of the approaches to control such potential viral contamination is to ensure the manufacturing process can adequately clear the potential viral contaminants. Viral clearance for production of human monoclonal antibodies is achieved by dedicated unit operations, such as low pH inactivation, viral filtration, and chromatographic separation. The process development of each viral clearance step for a new antibody production requires significant effort and resources invested in wet laboratory experiments for process characterization studies. Machine learning methods have the potential to help streamline the development and optimization of viral clearance unit operations for new therapeutic antibodies. The current work focuses on evaluating the usefulness of machine learning methods for process understanding and predictive modeling for viral clearance via a case study on low pH viral inactivation.

A Boosted Tree-Based Predictive Model for Business Analytics

“…By the same token, Antosz et al [21] sought to bring the operating costs down for manufacturers by using DT to implement the concept of lean maintenance. Moreover, Panjwani et al [22] implemented DT to predict the safe level of pathogens present during the processes involved in biological manufacturing to support streamlining the drug process development. In the supply chain context, Magalhães [23] utilized DT in final decision-making for online grocery to predict customer purchase trends.…”

New Opportunities and Challenges for Health Professionals in the era of Artificial Intelligence – Review

“…Moreover, machine learning (ML) methods may have the ability to help improve the development and optimize viral clearance unit operations for new therapeutic antibodies [8].…”